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Current medical management of dogs with congenital extrahepatic portosystemic shunt 
(cEHPSS) comprises the use of hepatic specific diet (HSD), lactulose and/or antibiotic 
therapy, aiming to control clinical signs of hepatic encephalopathy (HE). Meta‐analysis of 
people suffering from type C HE disclosed that antibiotic and disaccharide therapy are equally 
effective in controlling HE symptoms. 
A triple‐arm randomized clinical trial was designed to compare the efficacy of different 
treatment combinations [HSD and lactulose (HSD + LACT), HSD and metronidazole (HSD + 
METRO), and solely HSD] in controlling the clinical signs in dogs suffering from cEHPSS. 
Dogs were not allowed to be receiving medical therapy at the time of inclusion. The allocated 
‘initial’ treatment was continued for 4 weeks. Subsequently, all dogs received the combined 
treatment with HSD, LACT and METRO for an additional 2 weeks. Standardized 
questionnaires (assessing neurologic, gastrointestinal and urinary signs) were completed by 
the owners and a clinical score was calculated at diagnosis and at 4 and 6 weeks. 
Thirty‐six dogs were included, 12 were allocated to each group. Two dogs, 1 from HSD + 
LACT group and 1 from HSD + METRO groups were subsequently excluded due to 
concomitant diseases. Thirty‐three dogs had their clinical scores available at the 4‐weeks 
recheck and 27 dogs completed the trial until week 6 (10 HSD + LACT, 9 HSD + METRO, 
and 8 HSD). At diagnosis, the clinical scores were similar in all treatment groups (P = 0.89). 
Dogs in the “HSD + METRO” as well as the “HSD + LACT” group had a significant 
reduction in their clinical scores after the initial treatment compared to at diagnosis (P = 0.03 
and P = 0.002, respectively). In contrast, no clinical improvement was observed in the HSD 
group (P = 0.401). At 6 weeks, a trend to improvement was noticed in the HSD group (P = 
0.06), but no further improvement of the clinical score was detected in both other groups (P = 
1).  
Combination of HSD + LACT or HSD + METRO effectively reduces the clinical scores in 
cEHPSS dogs, while sole HSD therapy is not sufficient to control the same clinical signs. 
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